Peru has declared a 90-day national health emergency in response to a notable rise in cases of Guillain-Barre syndrome, a rare autoimmune disorder affecting the nervous system.
This decision comes as concerns about the potential link between the COVID vaccines and Guillain-Barre syndrome have been raised. Recent reports have indicated a higher incidence of the syndrome following the introduction of experimental COVID vaccine, particularly among older individuals.
In light of these developments, experts suggest close monitoring of individuals who have received the Pfizer RSV vaccine to identify any potential cases of Guillain-Barre syndrome.
According to clinical trial results published in the New England Journal of Medicine per CNBC, two older adults who participated in the clinical trials for the COVID shot developed Guillain-Barre syndrome. The findings raise concerns about the potential association between the “vaccine” and the syndrome.
“If RSVpreF vaccine is approved and recommended, these adverse events warrant close monitoring in future studies and with real-world data and postmarketing surveillance,” the scientists wrote. The study, which published Wednesday, was supported by Pfizer.
Additionally, a 40-year-old British man received compensation after being diagnosed with Guillain-Barre syndrome, which was believed to be linked to the shot.
The Sun Daily reported:
The Peruvian government declared a 90-day national health emergency Saturday due to an “unusual increase” of cases of Guillain-Barre syndrome, which total 165 with four deaths, reported Xinhua.
The decree, published in the official gazette El Peruano, details an action plan which has been drawn up with a budget of 12.12 million soles (US$3.3 million) with an aim to improve patient care in health facilities, reinforce case control and prepare informative material for the population and health personnel.
Among the measures were the acquisition of intravenous immunoglobulin and human albumin, as well as specialised diagnosis of the biological agents associated with the syndrome and assisted air transport for patients in emergency or critical condition.
Guillain-Barre syndrome is a rare disorder where the body’s immune system attacks part of the peripheral nervous system.
So far this year, at least 18 of the country’s 24 departments have reported at least one case of the syndrome.
